BriaCell Therapeutics Corp. (BCTX) company profile
Close on Nov 13, 2026Market cap $29.60MP/E –Yield –
About BriaCell Therapeutics
Pharmaceutical Preparations, SIC 2834
BriaCell Therapeutics Corp. is a biotechnology company focused on developing targeted immunotherapies for cancer management. The company concentrates on the clinical research and scientific advancement of cell therapies designed to stimulate the immune system against tumor targets, notably advanced metastatic breast cancer. Its operational activities encompass internal research initiatives, patent development, and collaborations alongside specialized institutions such as the National Cancer Institute to advance therapeutic pipelines for individuals living with complex malignancies.
Headquartered in West Vancouver, British Columbia, Canada, the company operates from its principal executive offices. Its corporate and development infrastructure includes dedicated laboratory facilities, administrative spaces, and specialized research equipment to support ongoing biotechnology development. Operating across its Canadian base, the entity organizes and oversees its clinical investigations and corporate management within the biotechnology and oncology sectors.
Summary of the business section of BriaCell Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- BriaCell Therapeutics Corp.
- Headquarters
- West Vancouver, A1
- Address
- 3rd Floor, Bellevue Centre, 235-15th Str V7T 2X1
- Phone
- (604) 921-1810
- Website
- briacell.com
- Employees
- 31, Jul 31, 2026
- Industry
- Pharmaceutical Preparations
- Incorporated in
- A1
- Fiscal year ends
- July 31
- Auditor
- MNP LLP, Toronto, Canada
Stock & identifiers
- Ticker
- BCTX
- Other tickers
- BCTXL, BCTXZ
- Exchange
- Nasdaq
- IPO date
- Feb 25, 2021
- Shares outstanding
- 9M, Oct 28, 2026
- Public float
- $37.40M, Jan 30, 2026
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-10 reverse, Aug 25, 2025; 1-for-15 reverse, Mar 12, 2025; 1-for-300 reverse, Jan 2, 2020
- SEC CIK
- 1610820
- CUSIP
- 107930307
- ISIN
- CA1079303071
- FIGI
- BBG0018783B6
- Share class FIGI
- BBG001SMHR46
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
No recent ownership filings by officers or directors
BriaCell Therapeutics's leadership is listed in its proxy statement, last filed Feb 12, 2026.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Option awards | Other | Total | vs. prior year |
|---|---|---|---|---|---|
| Dr. William V. Williams President and CEO | $711.72K | $68.90K | – | $780.62K | -28% |
| Mr. Gadi Levin CFO and Corporate Secretary | $485.36K | – | $50.00K | $535.36K | +3% |
| Dr. Giuseppe Del Priore Chief Medical Officer | $493.05K | – | – | $493.05K | -37% |
| Dr. Miguel A. Lopez-Lago Chief Scientific Officer | $447.55K | – | – | $447.55K | +14% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Feb 25, 2021
- Exchange
- Nasdaq
- Lock-up ends (est.)
- Aug 24, 2021
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of the date of this filing, we had thirty-one full-time employees, located in various US states including: NY, FL, PA, SC, NV, NJ and”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Feb 26, 2026 | Delisting | Notice of delisting from exchange (Form 25) |
| Jan 13, 2026 | Listing | Registration of securities on an exchange (Form 8-A) |
| Apr 24, 2025 | Listing | Registration of securities on an exchange (Form 8-A) |
| Aug 23, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jul 5, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Feb 25, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Feb 23, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |
| Jun 20, 2014 | Name change | Name changed from Ansell Capital Corp. to BriaCell Therapeutics Corp. |
See a number that looks wrong?